Table 2.
Odds ratios for invasive breast cancer incidence by VEGF promoter haplotype.
| Haplotype copies | Cases/controls | OR (95% CI) |
| AAG | ||
| 0 | 188/204 | 1.0 (ref.) |
| 1 | 149/224 | 0.69 (0.51–0.92) |
| 2 | 33/56 | 0.62 (0.38–1.00) |
| P (for trend) | 0.008 | |
| AGG | ||
| 0 | 260/342 | 1.0 (ref.) |
| 1 | 98/133 | 0.97 (0.71–1.33) |
| 2 | 12/9 | 1.71 (0.70–4.15) |
| P (for trend) | 0.63 | |
| CGG | ||
| 0 | 230/327 | 1.0 (ref.) |
| 1 | 125/144 | 1.27 (0.94–1.72) |
| 2 | 15/13 | 1.68 (0.78–3.61) |
| P (for trend) | 0.054 | |
| CGC | ||
| 0 | 161/220 | 1.0 (ref.) |
| 1 | 170/217 | 1.07 (0.80–1.43) |
| 2 | 39/47 | 1.18 (0.73–1.90) |
| P (for trend) | 0.47 | |
Haplotypes defined by polymorphisms at -2578, -1154, and -634 of the vascular endothelial growth factor gene. Includes 370 cases of invasive breast cancer and 484 controls with complete data on all three polymorphisms. Odds ratios (ORs) adjusted for birth year, year of blood draw, and race/ethnicity. CI, confidence interval.